Case report of non-gene editing CD7 CAR T cell therapy in CD7⁺ Sezary syndrome: preclinical validation and first-in-human use.

ABSTRACT:

Introduction

Sézary syndrome (SS) is a leukemic form of cutaneous T cell lymphoma (CTCL), distinguished from mycosis fungoides by the presence of cancerous lymphocytes in the blood and often bears very poor prognoses. SS treatment is palliative, and thus novel therapies are needed. The CD7 surface antigen is highly expressed and confined to the surface of T cells, therefore when present, serves as a promising target for immunotherapy.

Methods

Herein we describe the preclinical validation and clinical application of our non-gene editing CD7 targeted chimeric antigen receptor (CAR) T therapy to treat relapsed/refractory (r/r) CD7 expressing SS. The CD7 CAR construct possesses a "safety switch" (RTX) to enable rapid depletion of the CAR T treatment with administration of rituxi

SUBMITTER: Xu H 

PROVIDER: S-EPMC12354618 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature